Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating wound healing.

The company’s lead program is the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), a devastating orphan disease with no currently approved treatment options other than palliative care. To further advance research on DEB, Lotus Tissue Repair is collaborating with DEB Research Association (DEBRA) International and DEBRA of America on the first international web-based patient-reported registry at EBCare.org.